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Since experimental data led to the conclusion that NAZ does not bind into the Sudlow site II of Ibuprophen, the authors could complement they work by the same molecular docking analysis performed on the ibuprofen site. It will thus be possible to compare the docking results found with both sites and get a better idea of the value of the computed aggregate binding energy.
In addition, I found 2 corrections to make into the references: -Ref. 28 
Review form: Reviewer 3

Is the manuscript scientifically sound in its present form? No
Are the interpretations and conclusions justified by the results? No
Is the language acceptable? Yes
Do you have any ethical concerns with this paper? No
Have you any concerns about statistical analyses in this paper? No
Recommendation? Reject
Comments to the Author(s) Please see attached document (Appendix A).
Decision letter (RSOS-190922.R0)
01-Jul-2019
Dear Dr Hassan:
Manuscript ID: RSOS-190922 Title: "Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin" Thank you for submitting the above manuscript to Royal Society Open Science. Your paper was sent to reviewers and their comments are included at the bottom of this letter.
In view of the concerns raised by the reviewers, the manuscript has been rejected in its current form. However, a new manuscript may be submitted which takes into consideration these comments.
Please note that resubmitting your manuscript does not guarantee eventual acceptance, and that your resubmission will be subject to peer review before a decision is made.
You will be unable to make your revisions on the originally submitted version of your manuscript. Instead, revise your manuscript and upload the files via your author centre.
Once you have revised your manuscript, go to https://mc.manuscriptcentral.com/rsos and login to your Author Center. Click on "Manuscripts with Decisions," and then click on "Create a Resubmission" located next to the manuscript number. Then, follow the steps for resubmitting your manuscript.
Your resubmitted manuscript should be submitted by 29-Dec-2019. If you are unable to submit by this date please contact the Editorial Office.
We look forward to receiving your resubmission.
Yours sincerely, Dr Laura Smith Publishing Editor, Journals
Royal Society of Chemistry Thomas Graham House Science Park, Milton Road Cambridge, CB4 0WF Royal Society Open Science -Chemistry Editorial Office On behalf of the Subject Editor Professor Anthony Stace and the Associate Editor Mr Andrew Dunn ********************************************** REVIEWER(S) REPORTS: Associate Editor Comments to Author (): RSC Associate Editor: Comments to the Author: Although the reviewers make some positive comments, significant improvements are required to the docking studies before this manuscript could be suitable for publication. We would be happy to consider a revised version of this manuscript.
RSC Subject Editor:
Comments to the Author: (There are no comments.)
Reviewers' Comments to Author: Reviewer: 1
Comments to the Author(s) The authors carried out an interesting work characterizing the binding mode of NAZ with HAS by experimental and theoretical methods. The authors show a great amount of information in the spectrroscopic analysis. Nevertheless, the docking part it is short. For example, they never talk about why they chose that HAS crystal, and never talk about the validation of their docking procedure. They need to justify why that crystal?, because of its low X-ray resolution, and why that references ligand?. Only to mention some details.
Reviewer: 2
Comments to the Author(s) In this article, the authors investigated the interactions between Nazartinib (NAZ) a new anticancer EGFR tyrosine kinase inhibitor and human serum albumin (HSA) using experimental and theoretical approaches. Experiments of fluorescence quenching and UV-vis spectroscopic analysis, revealed the formation of a statically complex between NAZ and HSA and a binding constant for HSA-NAZ complex was computed in the studied temperature range. From these results, the thermodynamic parameters of the HSA-NAZ interaction were established by linear regression methods, which led to conclude that the non-covalent interaction was of electrostaticdriven type. The authors then identified the specific binding site of NAZ into HSA by ligand displacement studies using fluorescence techniques. They could conclude that NAZ binds into the HSA phenylbutazone site (namely Sudlow site 1). Finally, these experimental results were completed by molecular docking studies, which showed that NAZ binds the Sudlow site I on the HSA surface, through hydrogen bonding and electrostatic forces and not on the Ibuprophen site II.
This work is of some interest and I am favorable for a publication in Royal Society Open Science, provided that the authors provide additional data concerning the docking study. Since experimental data led to the conclusion that NAZ does not bind into the Sudlow site II of Ibuprophen, the authors could complement they work by the same molecular docking analysis performed on the ibuprofen site. It will thus be possible to compare the docking results found with both sites and get a better idea of the value of the computed aggregate binding energy.
In addition, I found 2 corrections to make into the references: 
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Review form: Reviewer 1
Is the manuscript scientifically sound in its present form? Yes
Are the interpretations and conclusions justified by the results? Yes
Is the language acceptable? Yes
Do you have any ethical concerns with this paper? Yes
Have you any concerns about statistical analyses in this paper? No
Recommendation?
Accept as is
Comments to the Author(s)
The work can be accepted for its publication.
Review form: Reviewer 2
Is the manuscript scientifically sound in its present form? Yes
Are the interpretations and conclusions justified by the results? Yes
Is the language acceptable? Yes
Do you have any ethical concerns with this paper? No
Have you any concerns about statistical analyses in this paper? No
Recommendation? Accept as is
Comments to the Author(s)
The authors generally met my expectations: they completed the part relating to docking and they thus performed the docking of NAZ on the second binding site of the HSA protein. Furthermore, the docking results are in agreement with the experimental results.
However, I note that reference 38 (which became reference 39), has not been corrected. The doi "10.5061/dryad.05c6v93" does not exist. If the corresponding link is not accessible, then this reference must be modified or removed.
Decision letter (RSOS-191595.R0)
28-Oct-2019
Title: Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin Manuscript ID: RSOS-191595 It is a pleasure to accept your manuscript in its current form for publication in Royal Society Open Science. The chemistry content of Royal Society Open Science is published in collaboration with the Royal Society of Chemistry.
The comments of the reviewer(s) who reviewed your manuscript are included at the end of this email. Comments to the Author(s) The work can be accepted for its publication.
Reviewer: 2
Comments to the Author(s) The authors generally met my expectations: they completed the part relating to docking and they thus performed the docking of NAZ on the second binding site of the HSA protein. Furthermore, the docking results are in agreement with the experimental results. However, I note that reference 38 (which became reference 39), has not been corrected. The doi "10.5061/dryad.05c6v93" does not exist. If the corresponding link is not accessible, then this reference must be modified or removed.
Ref: RSOS-190992 Title: Spectroscopic and molecular docking studies reveal binding characteristics of nazartinib (EGF816) to human serum albumin In this manuscript, the authors present an experimental study characterizing the binding of the drug NAZ to the protein HSA. The authors use computational molecular docking to gain insight into a plausible binding site for NAZ. Initial characterization involves fluorescence quenching which suggests that the ligand is either forming a static nonfluorescent complex or is diffusing through the system. They then use stern-volment, LB and double log correlations to gain insight into the mechanism and establish that the HAS-NAZ complex does indeed form. The thermodynamics of binding is then evaluated by observing changes to the binding constants with changes in temperature.
While the manuscript is mostly organized well, with the methods being presented logically and the results and interpretations discussed in detail, the manuscript requires significant improvements in order to be considered for publication.
However, there are some general issues that need to addressed before final publication of the manuscript: Figure 2 is not legible at all. The font size for the axes are too small to be legible.
Figures. The insets in
Molecular docking:
Can the authors clarify whether or not the residues were maintained to be flexible during the docking process? The MOE software should enable this with the induced fit docking protocol. Can the authors please highlight the important residues lining the binding site in Figure 10c ? The following publications might be useful in guiding the authors to improving the docking protocol and results in the manuscript.
